Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency  Christopher A. Bates, MD, Misoo C. Ellison, PhD, David A. Lynch, MD, Carlyne D. Cool, MD, Kevin K. Brown, MD, John M. Routes, MD  Journal of Allergy and Clinical Immunology  Volume 114, Issue 2, Pages 415-421 (August 2004) DOI: 10.1016/j.jaci.2004.05.057

Fig 1 A, HRCT: ground-glass abnormality and scattered irregular subpleural and intraparenchymal nodules. Hematoxylin and eosin: diffuse interstitial infiltrate composed of mature lymphocytes, plasma cells and histiocytes. The infiltrate widens the alveolar septa (arrows). Scattered interstitial lymphoid nodules are also evident. B, HRCT: irregular nodules, which are predominantly peribronchovascular; scattered ground-glass abnormality; and septal thickening. Hematoxylin and eosin: loose clusters of epithelioid histiocytes, multinucleated giant cells (arrow), and lymphocytes. C, HRCT: irregular nodules, many distributed along the bronchovascular structures. Hematoxylin and eosin: hyperplasia of the bronchus-associated lymphoid tissue (follicular bronchiolitis). The bronchiole (∗) is located to the right of the lymphoid follicle with a germinal center. The surrounding alveolar septa are thin and without evidence of inflammatory infiltrates. D, HRCT: subpleural consolidation with air bronchograms, surrounding ground-glass abnormality, and pleural effusion. Hematoxylin and eosin: scattered lymphocytes, plasma cells, and connective tissue filling the airspace. The surrounding septa are mildly thickened by a chronic inflammatory infiltrate that consists primarily of lymphocytes and plasma cells. Journal of Allergy and Clinical Immunology 2004 114, 415-421DOI: (10.1016/j.jaci.2004.05.057)

Fig 2 Kaplan-Meier survival plot demonstrating differences between the 2 groups of patients (GLILD vs non-GLILD). The median survival of 28.8 years in groups 1, 2, and 3B (solid line) is compared with the median survival of 13.7 years in group 3A (dashed line; P < .001). There is no statistical difference in survival between groups 1, 2, and 3B. Time is from the date of CVID diagnosis. Journal of Allergy and Clinical Immunology 2004 114, 415-421DOI: (10.1016/j.jaci.2004.05.057)